Assertio Announces $5.0 Million Insurance Settlement and General Corporate Updates

By adminFebruary 4, 2021Global News Feed

LAKE FOREST, Ill., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that its subsidiary Assertio Therapeutics, Inc. (“Assertio Therapeutics”) entered into a Confidential Settlement Agreement and Mutual Release (the “Settlement Agreement”) with its primary product liability insurer, Navigators Specialty Insurance Company and Navigators Insurance Company (“Navigators”).

Read more from the original source:
Assertio Announces $5.0 Million Insurance Settlement and General Corporate Updates

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering

By adminFebruary 4, 2021Global News Feed

BOSTON, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced a proposed public offering of $150 million of shares of its common stock. All shares in the offering will be offered by Rhythm. In addition, Rhythm intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of common stock at the public offering price, less the underwriting discount and commission.

The rest is here:
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

By adminFebruary 4, 2021Global News Feed

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in February:

Visit link:
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

Codexis Appoints Dr. Esther Martinborough to its Board of Directors

By adminFebruary 4, 2021Global News Feed

REDWOOD CITY, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced the appointment of Esther Martinborough, Ph.D., to its board of directors, expanding its membership to ten directors.

Read the rest here:
Codexis Appoints Dr. Esther Martinborough to its Board of Directors

Rubius Therapeutics to Participate in Guggenheim Healthcare Talks | 2021 Oncology Days

By adminFebruary 4, 2021Global News Feed

CAMBRIDGE, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, and the executive management team will participate in a fireside chat at the Guggenheim Healthcare Talks | 2021 Oncology Days on February 11, 2021, at 2:30 p.m. EST.

Read the original:
Rubius Therapeutics to Participate in Guggenheim Healthcare Talks | 2021 Oncology Days

Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

By adminFebruary 4, 2021Global News Feed

LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today reported that on February 1, 2021, the Company granted non-qualified stock options to purchase an aggregate of 57,550 shares of the Company’s common stock to four newly hired employees. These grants were made pursuant to the Company’s 2021 Inducement Stock Incentive Plan, were approved by the Company’s Inducement Grant Subcommittee of the board of directors, and were made as a material inducement to each employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.

View post:
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Psyence Group Presenting at Canaccord Genuity Conference "New Paradigms & Treatment Approaches in Mental Health"

By adminFebruary 4, 2021Global News Feed

TORONTO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) is pleased to announce that its Co-founder and CEO, Jody Aufrichtig will be presenting at the Canaccord Genuity conference "New Paradigms & Treatment Approaches in Mental Health", being held tomorrow, February 4, 2021 at 9am EST.

See the article here:
Psyence Group Presenting at Canaccord Genuity Conference "New Paradigms & Treatment Approaches in Mental Health"

Landos Biopharma Announces Pricing of Initial Public Offering

By adminFebruary 4, 2021Global News Feed

BLACKSBURG, Va., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the pricing of its initial public offering of 6,250,000 shares of common stock at the public offering price of $16.00 per share, for total gross proceeds of $100 million, before deducting underwriting discounts and commissions and offering expenses payable by Landos Biopharma. All of the shares of the common stock are being offered by Landos Biopharma.

Visit link:
Landos Biopharma Announces Pricing of Initial Public Offering

Iterum Therapeutics plc Announces $10 Million Bought Deal Public Offering of Ordinary Shares

By adminFebruary 4, 2021Global News Feed

DUBLIN, Ireland and CHICAGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 8,695,653 ordinary shares (or pre-funded warrants in lieu thereof) at a public offering price of $1.15 per share, less underwriting discounts and commissions. In addition, the Company has granted the underwriter an option for a period of 30 days to purchase up to an additional 1,304,347 ordinary shares on the same terms and conditions. All of the shares (or pre-funded warrants) are being offered by the Company. The offering is expected to close on or about February 8, 2021, subject to the satisfaction of customary closing conditions.

Originally posted here:
Iterum Therapeutics plc Announces $10 Million Bought Deal Public Offering of Ordinary Shares

Novavax and Government of Switzerland Announce Agreement in Principle to Supply COVID-19 Vaccine

By adminFebruary 4, 2021Global News Feed

Switzerland to purchase six million doses of the Novavax vaccine candidate, NVX-CoV2373 Switzerland to purchase six million doses of the Novavax vaccine candidate, NVX-CoV2373

Excerpt from:
Novavax and Government of Switzerland Announce Agreement in Principle to Supply COVID-19 Vaccine